Researchers at the Medical University of South Carolina are developing a two-part cellular therapy that could cure type 1 diabetes. Led by Dr. Leonardo Ferreira, the approach pairs lab-grown insulin-producing beta cells with engineered immune "bodyguard" cells called CAR-Tregs that prevent the body from destroying them. About 1.5 million Americans live with type 1 diabetes, which occurs when the immune system mistakenly attacks the pancreas.
The key innovation eliminates the need for lifelong immunosuppressive drugs. Traditional transplants require patients to take anti-rejection medications with serious side effects. By engineering regulatory T cells with chimeric antigen receptors, the team creates targeted protectors that shield the new beta cells from autoimmune attack. Preclinical studies in humanized mice show protective effects lasting up to one month.
The project, funded by a $1 million Breakthrough T1D award, involves collaboration with Dr. Holger Russ at the University of Florida for stem cell research and Dr. Michael Brehm at UMass Medical School for advanced mouse models. Ferreira says the therapy aims to work as an off-the-shelf solution for all type 1 diabetes patients at every stage of the disease.